Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
News|Articles|March 16, 2011
ASCO 2010: Treating CML
Dr. Sonali Smith discusses the newest developments in the treatment of CML.
Advertisement
Advertisement
Related to this article
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
Clinical Applications and the Future of Remote Endovascular Procedures
2
Building a Low-Dose Radiation Therapy Program for Benign Disease
3
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
4
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
5